Saturday 17 October 2026
Export ANAB’s income statement to Excel — free account
AnaptysBio, Inc.
ANAB Healthcare Biotechnology
AnaptysBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $234.6 million, up 157.0% from fiscal 2024. In the quarter to March 2026, revenue fell 7.98%, EPS fell 43.8% and free cash flow fell 141.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
46.61
2.10
−4.31%
Follow ANAB
| Mar '26 | Dec '25 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
4.56 | 3.96 | 3.35 | 3.46 | |
P/FCF ratio |
240.58 | 47.40 | 0.00 | 0.00 | |
P/Operating CF |
(40.92) | 9.48 | (20.77) | (10.60) | |
P/B ratio |
83.21 | 24.98 | 0.00 | 0.00 | |
Price to Tangible BV |
83.21 | 24.98 | 0.00 | 0.00 | |
EV/Sales |
3.34 | 2.64 | 1.90 | 1.32 | |
EV/EBITDA |
19.34 | 13.61 | 0.00 | 0.00 | |
EV/Operating CF |
173.44 | 31.49 | (2.22) | (1.28) | |
EV/FCF |
176.15 | 31.63 | (2.21) | (1.27) | |
Quick Ratio |
7.49 | 8.94 | 8.52 | 8.08 | |
Current Ratio |
7.58 | 9.07 | 8.68 | 8.22 | |
Net Debt/EBITDA |
8.42 | (4.64) | (7.28) | 9.78 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.62 | 0.55 | 0.40 | 0.32 | |
Operating CF/Net income |
0.49 | 1.98 | (1.81) | 1.04 | |
Capex/Depreciation |
(0.03) | 0.00 | 0.02 | 0.04 | |
Research and Development Expense of Revenue |
133.01% | 23.61% | 41.15% | 169.90% | |
Selling, General and Administrative Expense of Revenue |
102.53% | 14.59% | 13.38% | 47.65% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
55.63% | 7.86% | 12.00% | 41.50% | |
Graham Net Nets |
0.00 | 0.02 | (0.09) | (0.21) | |
Graham Number |
0.00 | 0.00 | 8.16 | 12.51 | |
Earnings Yield |
(2.30%) | (0.90%) | (13.72%) | (30.27%) | |
Free Cash Flow Yield |
0.42% | 2.11% | (25.58%) | (30.04%) | |
Revenue per Share |
0.89 | 3.76 | 2.74 | 0.77 | |
Operating CF per Share |
(0.90) | 3.41 | (0.98) | (1.40) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.90) | 3.41 | (0.98) | (1.40) | |
Cash per Share |
9.98 | 10.84 | 8.94 | 9.22 | |
Shareholders Equity per Share |
0.44 | 1.29 | (1.06) | (1.55) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.44 | 1.29 | (1.06) | (1.55) | |
Free Cash Flow |
(25.94) | 98.00 | (27.37) | (40.28) | |
Working Capital |
274.41 | 311.63 | 292.55 | 256.38 | |
Capital Expenditures |
(0.02) | 0.00 | (0.01) | (0.04) | |
Net Current Asset Value |
(0.83) | 23.07 | (51.86) | (88.08) | |
EV/EBIT |
19.04 | 12.95 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
26.00 | 19.41 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
21.82 | 37.31 | 43.94 | 15.21 | |
Average Payables |
6.82 | 3.94 | 3.24 | 4.11 | |
Average Assets |
375.87 | 424.11 | 423.26 | 381.31 | |
Average Common Equity |
23.38 | 54.04 | 27.48 | (17.43) |
Columns are period end dates